Yuki Ozato

Dr. Yuki Ozato


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MNMika Nakayama
Mika Nakayama
YOYuki Ozato
Yuki Ozato
YTYoshiko Tsuji
Yoshiko Tsuji
YAYasuko Arao
Yasuko Arao
COChihiro Otsuka
Chihiro Otsuka
HIHideshi Ishii
Hideshi Ishii
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by damage to the intestinal mucosa, which is caused by a combination of factors. These include genetic and epigenetic alterations, environmental influence, microorganism interactions, and immune conditions. Some populations with IBD show a cancer-prone phenotype. Recent studies have provided insight into the involvement of RNA modifications in the specific pathogenesis of IBD through regulation of RNA biology in epithelial and immune cells. Studies of several RNA modification-targeting reagents have shown preferable outcomes in patients with colitis. Here, we note a new awareness of RNA modification in the targeting of IBD and related diseases, which will contribute to early diagnosis, disease monitoring, and possible control by innovative therapeutic approaches.